) initiating coverage of the thing. In the report, Wunderlich wrote, "EW has been one of the premier growth stocks in the MedTech sector in recent years, driven by international success of the company's SAPIEN transcatheter heart valve, and growing enthusiasm for the upcoming U.S. launch. Recent concerns over the pace of market adoption in the U.S., however, combined with the market correction, have weighed on EW shares and may allow us an attractive buying opportunity." Wunderlich rated Edwards Lifesciences a HOLD with a price target of $75.00. Edwards Lifesciences closed Tuesday at $70.69.